Influenza h1n1 detected treatment protocol in mumbai
Reading File
Finding Sources
Searching the Web
H1N1 influenza treatment protocol Mumbai Maharashtra 2025 2026
Searching PubMed
influenza H1N1 treatment oseltamivir protocol
Finding Sources
Searching the Web
India MOHFW swine flu H1N1 category ABC classification treatment protocol oseltamivir
Finding Sources
Reading Web Page
https://careofchildren.com/h1n1-abc-it-is-everywhere
Reading File
Reading File
I now have comprehensive information from multiple sources. Here is the complete treatment protocol:
H1N1 Influenza (Swine Flu) - Detected Treatment Protocol in Mumbai
Current Epidemiological Status (Mumbai 2025-2026)
Mumbai consistently reports the highest number of H1N1 cases in Maharashtra. In 2025, Maharashtra recorded 942 influenza cases and 8 deaths (down ~60% from 2,351 cases/72 deaths in 2024), with Mumbai leading at 280 cases and 2 deaths. All private hospitals with treatment facilities are authorised to manage swine flu patients, and adequate stocks of oseltamivir are maintained.
Step 1 - Diagnosis / Case Detection
Influenza-Like Illness (ILI) is defined as:
- Fever ≥38°C (100.4°F) AND
- Cough / sore throat / nasal congestion / rhinorrhoea, AND
- Onset within the last 10 days
Confirmation:
- RT-PCR of nasopharyngeal/throat swab is the gold standard (most sensitive with nasopharyngeal samples)
- Rapid antigen tests are available but have lower sensitivity in adults
- Per Mumbai/Maharashtra protocol: do NOT wait for test confirmation to start treatment in Category B-ii and C patients
Step 2 - Case Categorization (MOHFW A/B/C System)
The Ministry of Health & Family Welfare (MOHFW) India uses a 3-tier classification for all H1N1/ILI cases:
Category A - Mild ILI
Symptoms: fever, cough/sore throat, runny nose, body aches, headache, with or without diarrhoea/vomiting.
No high-risk features, no breathlessness, no chest pain.
No high-risk features, no breathlessness, no chest pain.
| Management |
|---|
| No oseltamivir required |
| Symptomatic treatment only (antipyretics, analgesics, cough suppressants) |
| Plenty of warm fluids, rest, adequate nutrition |
| Home isolation - self-isolate for 7 days |
| Reassess at 24-48 hours; telephone follow-up |
| If deterioration occurs - escalate immediately to Category B/C |
Category B - Moderate Risk ILI
Category B-i - No high-risk group features but persistent symptoms:
- Fever not settling after 3 days
- High-risk group without breathlessness (see below)
Category B-ii - High risk group with ILI features:
- Children under 5 years, adults >65 years
- Pregnant women
- Chronic illness: diabetes, heart disease, chronic lung disease, chronic kidney/liver disease, cancer, immunosuppression (including HIV)
- Obesity (BMI >35)
- On long-term aspirin (children/teenagers)
- Healthcare workers
| Management |
|---|
| Home isolation + close monitoring |
| B-i: Oseltamivir may be started as per clinical assessment |
| B-ii: Start oseltamivir immediately |
| Telephone follow-up every 2-3 days |
| Immediate review if any signs of deterioration |
Category C - Severe / High Risk
Any of the following:
- Breathlessness / fast breathing / chest pain
- Altered sensorium / confusion
- Persistent vomiting preventing oral intake
- Cyanosis
- Blood in sputum
- Haemodynamic compromise (hypotension, tachycardia)
- SpO₂ < 94%
- Children with severe symptoms: dehydration, inability to feed, seizures, lethargy
| Management |
|---|
| Immediate hospitalisation |
| Start oseltamivir immediately - do NOT wait for test results |
| Intensive supportive care (oxygen, IV fluids, vasopressors if needed) |
| Consider ICU admission for respiratory failure, ARDS, multi-organ involvement |
Step 3 - Antiviral Treatment
Oseltamivir (Tamiflu) - First-Line
Oseltamivir is a neuraminidase inhibitor that blocks viral neuraminidase, preventing release of new virions from infected cells and limiting respiratory tract spread. It is active against both influenza A (H1N1) and B.
Adult Dosing:
| Indication | Dose | Duration |
|---|---|---|
| Treatment | 75 mg orally twice daily | 5 days |
| Severe/ICU (Cat C) | 75 mg twice daily (may extend) | Minimum 5 days; extend if critically ill |
| Chemoprophylaxis (contacts) | 75 mg orally once daily | 10 days |
Pediatric Dosing (Treatment - twice daily x 5 days):
| Weight | Dose |
|---|---|
| <15 kg | 30 mg BD |
| 15-23 kg | 45 mg BD |
| 24-40 kg | 60 mg BD |
| >40 kg | 75 mg BD |
Infants:
| Age | Dose |
|---|---|
| <3 months | 12 mg BD |
| 3-5 months | 20 mg BD |
| 6-11 months | 25 mg BD |
Available as capsules (75 mg) and suspension (12 mg/mL). Capsule contents may be dissolved in sugar syrup if suspension is unavailable.
Key Points:
- Most effective when started within 48 hours of symptom onset, but should still be given even after 48 hours in severe or high-risk cases
- In pregnancy, oseltamivir is the preferred agent (considered safe; benefits outweigh risks) - Goldman-Cecil Medicine
- Oseltamivir is renally cleared; dose reduction to 75 mg once daily for CrCl 10-30 mL/min
Zanamivir - Alternative
- Inhaled powder, twice daily x 5 days
- Used when oseltamivir is unavailable or there is documented oseltamivir resistance
- Not recommended in COPD/asthma (risk of bronchospasm)
Baloxavir Marboxil - Additional Option
- Cap-dependent endonuclease inhibitor; single oral dose
- FDA-approved; not yet routinely available in India's public health system
Antivirals NOT Recommended
- Amantadine and rimantadine are not effective against H1N1 - near-universal resistance exists in circulating strains
Step 4 - Supportive / ICU Management (Category C)
| Intervention | Details |
|---|---|
| Oxygen | Maintain SpO₂ ≥94%; high-flow O₂, NIV or mechanical ventilation as needed |
| IV fluids | Careful fluid management; avoid fluid overload in ARDS |
| Antipyretics | Paracetamol preferred; avoid NSAIDs in pregnancy |
| Antibiotics | Add empirically if bacterial co-infection suspected (S. aureus, Streptococcus - esp. in necrotising pneumonia post-influenza; consider MRSA coverage with vancomycin) |
| Corticosteroids | Not routinely recommended; evidence shows no benefit and possible harm in H1N1 pneumonia; use only for refractory ARDS per intensivist judgment |
| Prone positioning | For severe ARDS (PaO₂/FiO₂ <150 mmHg) |
Step 5 - Isolation & Infection Control
- Respiratory (droplet) precautions: surgical mask for patient, N95 for aerosol-generating procedures
- Hand hygiene with soap/water or alcohol-based sanitiser
- Patient isolated in single room if possible; cohort isolation otherwise
- Duration: 7 days from symptom onset OR 24 hours after resolution of fever (whichever is longer)
- Staff: use PPE; HCW with ILI symptoms must not work
Step 6 - Chemoprophylaxis (Post-Exposure)
Mass prophylaxis to all contacts is NOT advised. Targeted prophylaxis with oseltamivir 75 mg once daily x 10 days is given to:
- Contacts of confirmed H1N1 case who are in a high-risk group (pregnancy, diabetes, immunosuppression, chronic disease, extremes of age, healthcare workers)
- Other contacts: reassure, monitor, treat only if symptomatic
Step 7 - When to Test (Mumbai Protocol)
Testing (RT-PCR via NIV Pune network or BMC-designated labs) is prioritised for:
- All hospitalised patients (Category C)
- Category B patients with clinical uncertainty
- Healthcare workers with ILI
- Category A: testing generally not needed
Vaccination
- Annual influenza vaccination (now trivalent per WHO 2025-2026 guidance, as B/Yamagata lineage is considered extinct) is recommended for:
- Pregnant women (2nd and 3rd trimester) - high priority
- Healthcare workers
- Persons with diabetes, hypertension, chronic cardiac/pulmonary/renal disease
- Adults >65 years, children <5 years
Sources: MOHFW India H1N1 Categorization Guidelines | Maharashtra Public Health Dept 2025 data | Goldman-Cecil Medicine (26th Ed.) | Fishman's Pulmonary Diseases & Disorders | WHO/Medscape H1N1 guidelines
Note: Always confirm the current oseltamivir stock availability with BMC's epidemic cell or the state health department at time of outbreak. For real-time Mumbai H1N1 alerts, contact BMC's Integrated Disease Surveillance Programme (IDSP) cell.
This is a shared conversation. Sign in to Orris to start your own chat.